Literature DB >> 29680519

Is DPP4 activity increased in PCOS?

Letícia Dinis da C Braga1, Amelio F Godoy-Matos2, Priscila de Oliveira Siciliano2, José Otávio do Amaral Corrêa3, Denise Pires Carvalho4.   

Abstract

AIMS: Dipeptidyl peptidase-4 (DPP4) is an adipokine with greater expression in visceral fat and related with insulin resistance (IR). Polycystic ovary syndrome (PCOS) is also associated with IR. Our study aims to evaluate DPP4 activity in PCOS.
MATERIALS AND METHODS: Thirty PCOS patients were compared to 28 healthy women. Body composition by dual X-ray absorptiometry (DXA), plasma activity of DPP4 and biochemical variables were performed. All participants underwent an oral glucose tolerance test for insulin and glucose analysis.
RESULTS: DPP4 activity was similar in both groups (PCOS 5823 ± 926 vs Control 5501.8 ± 975; p = 0.20). PCOS patients were more IR with lower levels of SHBG (32 vs 47, p = 0.02) and Matsuda index (15.6 vs 20.4, p = 0.03) and higher HOMA-IR (2.8 vs 1.7, p < 0.01), in addition to increased levels of testosterone (55 vs 25, p < 0.01). DPP4 was correlated to HbA1c (r = 0.279, p = 0.03), HDL-c (r = -0.28, p = 0.03) and SHBG (r = -0.256, p = 0.05).
CONCLUSIONS: Although PCOS was well characterized as IR and hyperandrogenic, DPP4 was not different in this group. However, a relationship between DPP4 and markers of IR were found. More studies are warranted.
Copyright © 2018 Diabetes India. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Adipokine; Dipeptidyl peptidase-4; Insulin resistance; Polycystic ovary syndrome

Mesh:

Substances:

Year:  2018        PMID: 29680519     DOI: 10.1016/j.dsx.2018.04.032

Source DB:  PubMed          Journal:  Diabetes Metab Syndr        ISSN: 1871-4021


  6 in total

1.  DPP4 Activities Are Associated with Osteopenia/Osteoporosis and Fracture Risk in Newly Diagnosed Type 2 Diabetes.

Authors:  Min Qiu; Shuheng Zhai; Da Liu
Journal:  Int J Endocrinol       Date:  2020-11-27       Impact factor: 3.257

2.  Knockdown of DPP4 promotes the proliferation and the activation of the CREB/aromatase pathway in ovarian granulosa cells.

Authors:  Lina Lin; Liman Wang
Journal:  Mol Med Rep       Date:  2022-01-11       Impact factor: 2.952

3.  Serum dipeptidyl peptidase-4 activity and progranulin level in polycystic ovary syndrome patients.

Authors:  Maryam Abolghasemi; Soleiman Mahjoub; Sedighe Esmaeilzadeh
Journal:  Caspian J Intern Med       Date:  2022

4.  Quantitative Proteomics Reveals That a Prognostic Signature of the Endometrium of the Polycystic Ovary Syndrome Women Based on Ferroptosis Proteins.

Authors:  Jian Zhang; Nan Ding; Wenhu Xin; Xin Yang; Fang Wang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-14       Impact factor: 6.055

5.  Imaging-Based Body Fat Distribution in Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis.

Authors:  Shiqin Zhu; Zeyan Li; Cuiping Hu; Fengxuan Sun; Chunling Wang; Haitao Yuan; Yan Li
Journal:  Front Endocrinol (Lausanne)       Date:  2021-09-09       Impact factor: 5.555

Review 6.  The Potential Effect of Rhizoma coptidis on Polycystic Ovary Syndrome Based on Network Pharmacology and Molecular Docking.

Authors:  Liyun Duan; Xuedong An; Yuehong Zhang; Shenghui Zhao; Rongrong Zhou; Yingying Duan; Yuqing Zhang; Xinmin Liu; Fengmei Lian
Journal:  Evid Based Complement Alternat Med       Date:  2021-07-08       Impact factor: 2.629

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.